Viewing nowCombinationJanumics Tablet 50/500 mg
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.

MFDS item code 201503178 · Approved 2015.05.27 · Insurance code 678600500
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to improve blood sugar control in patients with type 2 diabetes. It assists blood sugar management by complementing dietary and exercise therapies through the combined use of sitagliptin and metformin. This comprehensive treatment aids in effectively controlling blood sugar levels, making it suitable for patients with type 2 diabetes who require blood sugar control.
For antidiabetic therapy, the dose of this drug should be determined based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is one 50/500 mg tablet twice daily; the dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, section 2. Patients in whom this drug is contraindicated). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this drug from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, section 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control, so caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, section 2. Patients in whom this drug is contraindicated).
This medication consists of two main ingredients, each used in the treatment of diabetes. First, this medication contains sitagliptin, which helps control blood sugar but can rarely cause serious allergic reactions or skin disorders. If such symptoms occur, you should stop taking this medication immediately and consult a doctor. Additionally, sitagliptin carries the risk of causing pancreatitis, an inflammation of the pancreas, so if you experience symptoms like abdominal pain or vomiting while taking it, you must inform your healthcare provider immediately. Second, this medication also contains metformin, which lowers blood sugar levels but can rarely cause a serious metabolic disorder known as lactic acidosis. Symptoms of lactic acidosis may include muscle pain, weakness, difficulty breathing, and abdominal pain, and if these symptoms occur, you should receive medical attention promptly. This medication should not be administered to patients with moderate to severe renal impairment, severe infections or dehydration, congestive heart failure, pregnant or breastfeeding women. During treatment, regular monitoring of kidney function is necessary, and if a sudden decline in kidney function is suspected, the use of this medication should be discontinued. Moreover, this medication can cause hypoglycemia, so you should pay particular attention to symptoms of low blood sugar, especially when taken in conjunction with other hypoglycemic agents, and take appropriate measures if they arise. It is advisable to avoid alcohol while taking this medication, and to stop taking it for a period before and after surgery, resuming only after kidney function has recovered. Rarely, severe joint pain or skin blistering has been reported; if such symptoms occur, you should inform your doctor. Finally, this medication is not recommended for use in children under 18 as its safety and efficacy have not been established.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent moisture exposure and keep it at room temperature, between 1 to 30 degrees Celsius. Proper storage helps maintain the effectiveness of the medication and prevents degradation.
Bright pink oval film-coated tablet
30 tablets (10 tablets/PTP x 3) - 30 tablets/PTP
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Dasan Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.